 |
|
Recent News Releases
News Note: Biomarker Can Distinguish Between Cell Death and DNA Damage
(Posted: 05/08/2009) - NCI researchers have identified a molecular ring pattern that could be used as a biomarker to identify and distinguish between cells that are programmed for death from cells that have a particular type of DNA damage. Such biomarkers could provide new tools for basic cellular biology research, but also help to mark cell death in clinical samples and monitor the efficacy of anticancer regimens.
Targeted Immune Cells Shrink Tumors in Mice
(Posted: 02/09/2009, Updated: 05/07/2009) - Researchers have generated altered immune cells that are able to shrink, and in some cases eradicate, large tumors in mice. The immune cells target mesothelin, a protein that is highly expressed, or translated in large amounts from the mesothelin gene, on the surface of several types of cancer cells.
New Early Detection Studies of Lung Cancer in Non-Smokers Launched Today
(Posted: 05/04/2009) - Government and private sector cancer scientists today launched a research partnership to find biomarkers for lung cancer that develops in people who have never smoked. The research studies are designed to create a better understanding of the biology of lung cancer and to develop a test to detect early-stage lung cancer in lifetime nonsmokers.
National Cancer Institute's Plan to Accelerate Cancer Research Announced
(Posted: 04/20/2009) - At the American Association for Cancer Research 100th Annual Meeting 2009 in Denver, NCI Director John E. Niederhuber, M.D., announced major details, such as funding more grants, development of a platform for personalized cancer care, and an accelerated cancer genetics program, that will move cancer research forward in this new economic environment.
 
Researchers Discover Potential Functional Role of Genetic Variation in Prostate Cancer Risk
(Posted: 04/20/2009) - Researchers have described how a common genetic variation may be involved in the development of prostate cancer. The variant occurs in a gene known to be involved in prostate function. The study, which included a team of researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, uncovered how a small change in the DNA of the gene impacts the biology of prostate cancer risk.
NCI MEDIA AVAILABILITY: Dr. John E. Niederhuber to Address the American Association for Cancer Research on NCI Plan to Accelerate Cancer Research
(Posted: 04/16/2009) - John E. Niederhuber, M.D., director of the NCI, addressed the American Association for Cancer Research 100th Annual Meeting 2009 in Denver Monday, April 20, 2009, during a Special Session. The talk focused on opportunities to hasten our progress against cancer and to conduct exciting new science, made possible, in part, by NCI's nearly three percent budget increase this year.
First Phase 0 Oncology Trial Shows Effectiveness of New Drug on Its Target
(Posted: 04/13/2009) - The first phase 0 clinical trial of a drug in cancer treatment, involving 13 patients with advanced cancers, showed that the drug, ABT-888, affected its target and was well tolerated. Most importantly, this trial showed that it is possible to enroll a small number of patients, treat them with a low dose of a new drug, identify whether the desired target of the drug was affected, and obtain all of this critical information relatively quickly.
Researchers Identify Genetic Variations That May Increase Risk of Breast Cancer
(Posted: 03/29/2009) - Researchers have identified new genetic variations in two regions of DNA -- located on chromosomes 1 and 14 -- that may be associated with the risk of sporadic breast cancer. This study also confirms some of the previously identified associations between specific regions in the genome and breast cancer risk.
1 2 3 Next >
View Archive of News Releases
|
|
|
